The UDIC has been selected to initiate a line of several clinical trials with this D1 dopamine agonist, with a similar mechanism of action to Apomorphine. It will be evaluated in initial Parkinson’s and also in advanced Parkinson’s disease, as add on levodopa therapy. An open label extension is planned.
